EGFR and familial pancreatic carcinoma: Adding low-dose simvastatin (LD-Sim) to gemcitabine in treatment of advanced pancreatic cancer does not provide additional benefit but it also does not result in greater toxicity compared to gemcitabine alone. Since data point to an emerging role of statins in overcoming resistance to anti-epidermal growth factor receptor (EGFR) treatments, these results support further evaluation of efficacy and safety of combined LD-Sim and anti-EGFR agents (e.g., erlotinib or cetuximab) plus gemcitabine for treating advanced and metastatic PC